US FDA's draft biosimilar labeling guidance falls short on patient safety measures, says AfPA

5 April 2016

A critical response has been given to draft new guidance issued by the US Food and Drug Administration on the labeling of biosimilars by the Alliance for Patient Access (AfPA).

This group is a network of physicians who work to ensure patient access to approved therapies, and it has been quick to comment after the FDA last week invited feedback on its recommendations for the new labeling of biosimilar products.

Labeling is important in communicating a product’s safety and effectiveness to the practitioners who decide whether to prescribe it to patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK